Drug Database · Clinicians

Fluorouracil

Brands (18) Fura, Raciwel, Chemoflura…Show all

US brand (reference label): FAVLYXA; not a Philippine-registered brand.

Nucleoside Metabolic Inhibitor (Nucleic Acid Synthesis Inhibitors) US FDA class
Antineoplastics ( cell cycle-specific agents); Antineoplastic agent (pyrimidine analogue); and others PH FDA category

Rx · Prescription drug20 PH productsPNF-listedVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 1daf714b-704c-4bcc-b6e0-6f0eb2bfe66b, version date October 23, 2026 (FAVLYXA · Avyxa Pharma, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum
  • Adenocarcinoma of the Breast
  • Gastric Adenocarcinoma
  • Pancreatic Adenocarcinoma
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE FAVLYXA is indicated for the treatment of patients with: FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum (1.1) Adenocarcinoma of the Breast (1.2) Gastric Adenocarcinoma (1.3) Pancreatic Adenocarcinoma (1.4) 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma

Contraindications

4 CONTRAINDICATIONS None. None. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • FAVLYXA is recommended for administration either as an intravenous bolus or as an intravenous infusion. (2.1)
  • Adenocarcinoma of the Colon and Rectum In combination with leucovorin or as a component of a multidrug chemotherapy regimen that includes leucovorin (infusional regimen): 400 mg/m 2 for one dose, followed by 2,400 mg/m 2 to 3,000 mg/m 2 over 46 hours on day 1 of each 2-week cycle or In combination with leucovorin (bolus regimen): 500 mg/m 2 on days 1, 8, 15, 22, 29 and 36 of each 8-week cycle. (2.2)
  • Adenocarcinoma of the Breast in combination with a cyclophosphamide-based multidrug regimen: 500 mg/m 2 or 600 mg/m 2 on days 1 and 8 of each 28-day cycle (bolus regimen). (2.2)
  • Gastric Adenocarcinoma in combination with a platinum-containing multidrug regimen: 200 mg/m 2 to 1,000 mg/m 2 over 24 hours (infusional regimen). (2.2)
  • Pancreatic Adenocarcinoma in combination with leucovorin or as a component of a multidrug chemotherapy regimen that includes leucovorin: 400 mg/m 2 on day 1, followed by 2,400 mg/m 2 over 46 hours every 2 weeks (infusional regimen). (2.2)
  • Refer to Section 2.3 for dosage modifications due to adverse reactions.
2.1 Evaluation and Testing for DPD Deficiency

2.1 Evaluation and Testing for DPD Deficiency Before Initiating FAVLYXA Prior to initiating FAVLYXA, test patients for genetic variants of the DPYD gene unless immediate treatment is necessary. An FDA-authorized test for the detection of the DPYD gene to identify patients at risk of serious adverse reactions with FAVLYXA is not currently available.

Currently available tests used to identify DPYD variants may vary in accuracy and design (e.g., which DPYD variant(s) they identify). Avoid use of FAVLYXA in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency. No FAVLYXA dose has been proven safe for patients with complete DPD deficiency.

For patients with partial DPD deficiency, individualize the dosage and modify based on tolerability and intent of treatment [see Warnings and Precautions (5.1)].

2.2 Recommended Dosage

2.2 Recommended Dosage FAVLYXA is recommended for administration either as an intravenous bolus or as an intravenous infusion. Dosage recommendations are in Table 1. Table 1: Recommended dosage of FAVLYXA Indication Recommended Dosage Duration of Treatment Adenocarcinoma of the Colon and Rectum In combination with leucovorin or as a component of a multidrug chemotherapy regimen that includes leucovorin 400 mg/m 2 for one dose, followed by 2,400 mg/m 2 to 3,000 mg/m 2 over 46 hours on day 1 of each 2-week cycle Until disease progression or unacceptable toxicity.

In combination with leucovorin alone (bolus regimen) 500 mg/m 2 on days 1, 8, 15, 22, 29 and 36 of each 8-week cycle Until disease progression or unacceptable toxicity. Adenocarcinoma of the Breast In combination with cyclophosphamide-based multidrug regimen (bolus regimen) 500 mg/m 2 or 600 mg/m 2 on days 1 and 8 of each 28-day cycle Until disease progression or unacceptable toxicity or 6 cycles Gastric Adenocarcinoma In combination with a platinum-containing multidrug regimen 200 mg/m 2 to 1,000 mg/m 2 over 24 hours Frequency in each cycle and length of each cycle depend on dose of FAVLYXA and specific regimen Pancreatic Adenocarcinoma In combination with leucovorin or as a component of a multidrug chemotherapy regimen that includes leucovorin 400 mg/m 2 on day 1, followed by 2,400 mg/m 2 over 46 hours every 2 weeks Until disease progression or unacceptable toxicity.

2.3 Dosage Modifications for Adverse Reactions Withhold

2.3 Dosage Modifications for Adverse Reactions Withhold FAVLYXA for the following adverse reactions. Depending on the severity of the adverse reaction, either discontinue or resume FAVLYXA at a reduced dosage upon resolution or improvement to Grade 1: Grade 3 or 4 diarrhea [see Warnings and Precautions (5.5)] Grade 2 or 3 palmar-plantar erythrodysesthesia (hand-foot syndrome) [see Warnings and Precautions (5.6)] Grade 3 or 4 mucositis [see Warnings and Precautions (5.8)] Grade 4 myelosuppression [see Warnings and Precautions (5.7)] There is no recommended dose for resumption of FAVLYXA administration following development of any of the following adverse reactions; consider permanent discontinuation of FAVLYXA following: Development of angina, myocardial infarction/ischemia, arrhythmia, or heart failure in patients with no history of coronary artery disease or myocardial dysfunction [see Warnings and Precautions (5.2)] Hyperammonemic encephalopathy [see Warnings and Precautions (5.3)] Neurologic toxicity including acute cerebellar syndrome [see Warnings and Precautions (5.4)]

2.4 Preparation and Administration

2.4 Preparation and Administration FAVLYXA is a hazardous drug. Follow applicable special handling and disposal procedures 1. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Direct Intravenous Bolus Injection Preparation Select the appropriate number of vial(s) based on the prescribed dose.

Withdraw the calculated dose into a sterile syringe. If using a single-dose vial, discard partially used or empty single-dose vials. If using a multiple-dose vial, after first use, store the partially used multiple-dose vial in the original carton at room temperature 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion of the multiple-dose vial after 28 days.

Administration Administer FAVLYXA as an intravenous bolus through an established intravenous line over 2 to 5 minutes. Do not administer in the same intravenous line concomitantly with other medicinal products. Storage If the dose is not administered, attach a tip cap to the syringe prior to storage. The syringe can be stored at room temperature 20°C to 25°C (68°F to 77°F) for up to 4 hours.

For Intravenous Infusion Preparation Select the appropriate number of vial(s) based on the prescribed dose. Withdraw the calculated dose into a sterile syringe. Dilute the calculated dose in an appropriate amount of 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, to prepare an infusion solution. If using a single-dose vial, discard partially used or empty single-dose vials.

If using a multiple-dose vial, after first use, store the partially used multiple-dose vial in the original carton at room temperature 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion of the multiple-dose vial after 28 days. Administration Do not administer in the same intravenous line concomitantly with other medicinal products.

For intravenous infusion regimens, administer through a central venous line using an infusion pump. Storage If not used immediately, the diluted FAVLYXA can be stored at room temperature 20°C to 25°C (68°F to 77°F) for up to 24 hours.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of FAVLYXA in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Reported clinical experience has not identified differences in safety or effectiveness between the elderly and younger patients.

Administration

2.2 Recommended Dosage FAVLYXA is recommended for administration either as an intravenous bolus or as an intravenous infusion. Dosage recommendations are in Table 1. Table 1: Recommended dosage of FAVLYXA Indication Recommended Dosage Duration of Treatment Adenocarcinoma of the Colon and Rectum In combination with leucovorin or as a component of a multidrug chemotherapy regimen that includes leucovorin 400 mg/m 2 for one dose, followed by 2,400 mg/m 2 to 3,000 mg/m 2 over 46 hours on day 1 of each 2-week cycle Until disease progression or unacceptable toxicity. In combination with leucovorin alone (bolus regimen) 500 mg/m 2 on days 1, 8, 15, 22, 29 and 36 of each 8-week cycle Until disease progression or unacceptable toxicity. Adenocarcinoma of the Breast In combination with cyclophosphamide-based multidrug regimen (bolus regimen) 500 mg/m 2 or 600 mg/m 2 on days 1 and 8 of each 28-day cycle Until disease progression or unacceptable toxicity or 6 cycles Gastric Adenocarcinoma In combination with a platinum-containing multidrug regimen 200 mg/m 2 to 1,000 mg/m 2 over 24 hours Frequency in each cycle and length of each cycle depend on dose of FAVLYXA and specific regimen Pancreatic Adenocarcinoma In combination with leucovorin or as a component of a multidrug chemotherapy regimen that includes leucovorin 400 mg/m 2 on day 1, followed by 2,400 mg/m 2 over 46 hours every 2 weeks Until disease progression or unacceptable toxicity.

2.4 Preparation and Administration FAVLYXA is a hazardous drug. Follow applicable special handling and disposal procedures 1 . Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Direct Intravenous Bolus Injection Preparation Select the appropriate number of vial(s) based on the prescribed dose. Withdraw the calculated dose into a sterile syringe. If using a single-dose vial, discard partially used or empty single-dose vials. If using a multiple-dose vial, after first use, store the partially used multiple-dose vial in the original carton at room temperature 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion of the multiple-dose vial after 28 days. Administration Administer FAVLYXA as an intravenous bolus through an established intravenous line over 2 to 5 minutes. Do not administer in the same intravenous line concomitantly with other medicinal products. Storage If the dose is not administered, attach a tip cap to the syringe prior to storage. The syringe can be stored at room temperature 20°C to 25°C (68°F to 77°F) for up to 4 hours. For Intravenous Infusion Preparation Select the appropriate number of vial(s) based on the prescribed dose. Withdraw the calculated dose into a sterile syringe. Dilute the calculated dose in an appropriate amount of 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, to prepare an infusion solution. If using a single-dose vial, discard partially used or empty single-dose vials. If using a multiple-dose vial, after first use, store the partially used multiple-dose vial in the original carton at room temperature 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion of the multiple-dose vial after 28 days. Administration Do not administer in the same intravenous line concomitantly with other medicinal products. For intravenous infusion regimens, administer through a central venous line using an infusion pump. Storage If not used immediately, the diluted FAVLYXA can be stored at room temperature 20°C to 25°C (68°F to 77°F) for up to 24 hours.

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 25 mg/mL (250 mg/10 mL, 50 mg/mL (250 mg/5 mL, 50 mg/mL (500 mg/10 mL, 250 mg/5 mL (50 mg/mL
  • Solution for injection: 25 mg/mL, 50 mg/mL, 500 mg/10 mL
  • ) solution for i.v. infusion: 50 mg/mL (500 mg/10 mL and 1 g/20 mL
  • ) solution for i.v. injection/infusion: 50 mg/mL (500 mg/10 mL
  • ) solution for injection/ infusion: 50 mg/mL (500 mg/10 mL
  • Solution for i.v. injection: 50 mg/mL

Registered products in the Philippines

20 products registered with the Food and Drug Administration (FDA) Philippines list Fluorouracil as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Flourouracil (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products20
Philippine FDA-registered products for Fluorouracil
Package insert
ChemofluraFluorouracil
50 mg/mL (500 mg/10 mL) Solution for Injection (IV/IV Infusion)USP Type I Amber Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Neon Laboratories Ltd.India
Ambica International Corporation
DRP-5526
Sep 26, 2029
Fin-5FUFluorouracil
50 mg/mL (500 mg/10 mL) Solution For Injection (I.V.)10 mL Type I moulded clear glass vial with 20 mm grey bromobutyl rubber plug and aluminum seal with flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Finstad Inc.
DRP-13786
Apr 19, 2028
FlucelFluorouracil
50 mg/mL Solution For Injection (IV)USP Type I Amber Glass Ampoule x 5 mL Box of 5's; USP Type I Amber Glass Ampoule x 10 mL Box of 5's
RxVAT-exempt
CELON LABORATORIES PRIVATE LIMITEDIndia
I.E. Medica, Inc.
DRP-6441
Jan 21, 2029
FluciloFluorouracil
25 mg/mL (250 mg/10 mL) Solution For Injection (IV)Type I Borosilicate Glass Ampoule x 10 mL (Box of 5's)
RxVAT-exempt
Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
DRP-11406
Mar 9, 2027
FluoracilexFlourouracilVariant spelling
50 mg/mL (500 mg/10 mL) Solution for I.V. Injection/Infusion10 mL (net content) USP Type I Clear and Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Seal with White Plastic Flip-Off Cap (Box of 5's)
Rx
Laboratorio Kemex S.A.
Delex Pharma International, Inc.
DRP-11689
Apr 13, 2027
FluorasaphFluorouracil
50 mg/mL Solution for I.V. InjectionUSP Type I clear glass vial with rubber stopper and flip-off seal x 5 mL and 10 mL (Box of 1's).
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-13564
Mar 9, 2028
FluorocareFluorouracil
500 mg /10 mL Solution for Injection (I.V./I.V. Infusion)USP Type I Amber Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Naprod Lifesciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-10581
Mar 29, 2032
FluoroGet-500Fluorouracil
50mg/mL (500mg/10mL) Solution for Injection (IV Infusion)20mL-Capacity Type I Amber Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Flip- Off Seal Cap x 10mL (Net content) (Box of 1's)
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-16386
Feb 26, 2030
FluorogoldFluorouracil
250 mg/5 mL (50 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Detoxicare Philippines, Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corporation
DRP-4820-03
May 2, 2028
FluororacFluorouracil
50 mg/mL (250 mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 5 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Diafarm, Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4820-01
May 2, 2028
FluorouxilFluorouracil
50 mg/mL (500 mg/10 mL) Solution for Injection (IV/IV Infusion)USP Type I Amber Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Neon Laboratories Ltd.India
Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation
DRP-5526-01
Sep 26, 2029
FluoroxilFluorouracil
50 mg/mL Solution for Injection (IV)USP Type I brown glass vial with chlorobutyl rubber stopper (Box of 10's x 5 mL; Box of 10's x 10 mL)
RxVAT-exempt
Ildong Pharmaceutical Co., Ltd.Republic of Korea
International Apex Pharmaceutical, Inc.
DR-XY46634
Aug 19, 2029
FucilFluorouracil
50 mg / mL (500 mg/ 10 mL) Solution for Injection/ Infusion (IV)USP Type I Clear Colorless Glass Vial x 10 mL with blue color flip-off cap (Box of 1's)
RxVAT-exempt
Beacon Pharmaceuticals Ltd.Bangladesh
UNILAB, Inc.
DR-XY41191
Sep 4, 2027
FuraFluorouracil
25 mg/mL Solution for Injection (IV)Type I Clear and Colorless Glass Vial Sealed with Grey Bromobutyl Rubber Stopper, Aluminum Seal and Orange Polypropylene Flip-off Cap x 15 mL (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Co. Ltd.China
Amb HK Enterprises Inc.
DRP-17219
Oct 20, 2030
FuraFluorouracil
50 mg/mL Solution for Injection (IV)Type I Clear and Colorless Glass Vial Sealed with Grey Bromobutyl Rubber Stopper, Aluminum Seal and Orange Polypropylene Flip-off Cap x 15 mL (Box of 1's)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Co. Ltd.China
Amb HK Enterprises Inc.
DRP-17218
Oct 20, 2030
RacifluoroFluorouracil
250 mg/5 mL (50 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 10 mL Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
Genace Pharma DistributorImporter: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4820-02
May 2, 2028
RaciwelFluorouracil
250 mg/5 mL (50 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 5 mL Box of 1’s; USP Type I Amber Glass Vial x 10 mL Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
Multi Product Line Pharma, Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp.
DRP-4820
May 2, 2028
RaciwelFluorouracil
50mg/mL Solution for Injection (IV)Type I Amber Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Purple Flip- Off Cap x 20mL (Box of 1's)
RxVAT-exempt
Getwell PharmaceuticalsIndia
AGB Pharmaceutical Trading and Consultancy Corporation
DRP-16986
Sep 4, 2030
UrabeneFluorouracil
50 mg/mL Solution For Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's); USP Type I Amber Glass Ampoule x 10 mL (Box of 5's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-6441-02
Jan 21, 2029
UtoralFluorouracil
50 mg/mL (500 mg/10 mL and 1 g/20 mL) Solution for I.V. InfusionAmber Glass Vial x 10 mL and 20 mL Box of 10's
RxVAT-exempt
Korea United Pharm, Inc.Korea
Qualimed Pharma, Inc.
DR-XY25050
Aug 27, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: FAVLYXA contains 25 mg/mL fluorouracil as a colorless to light yellow clear solution and is available as: 250 mg/10 mL (25 mg/mL) in a single-dose vial. 2,500 mg/100 mL (25 mg/mL) in a multiple-dose vial. Injection: 250 mg/10 mL (25 mg/mL) in a single-dose vial. (3) 2,500 mg/100 mL (25 mg/mL) in a multiple-dose vial. (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Cardiotoxicity: FAVLYXA can cause cardiotoxicity, including angina, myocardial infarction/ischemia, arrhythmia, and heart failure. Withhold FAVLYXA for cardiac toxicity. (5.2)
  • Hyperammonemic Encephalopathy: Altered mental status, confusion, disorientation, coma, or ataxia with elevated serum ammonia level can occur within 72 hours of initiation of FAVLYXA. Withhold FAVLYXA and initiate ammonia-lowering therapy. (5.3)
  • Neurologic Toxicity: FAVLYXA can cause acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances. Withhold FAVLYXA for neurologic toxicity. (5.4)
  • Diarrhea: FAVLYXA can cause severe diarrhea. Withhold FAVLYXA for severe diarrhea until resolved. (5.5)
  • Palmar-Plantar Erythrodysesthesia Syndrome: Based on severity, withhold FAVLYXA until resolved or decreased to Grade 1, then resume at a reduced dose. (5.6)
  • Myelosuppression: FAVLYXA can cause severe and fatal myelosuppression. Withhold FAVLYXA until severe myelosuppression resolves, then resume at a reduced dose. (5.7)
  • Mucositis: FAVLYXA can cause severe mucositis. Withhold FAVLYXA until resolved or decreased to Grade 1, then resume at a reduced dose. (5.8)
  • Increased Risk of Bleeding with Concomitant Use of Warfarin: Concurrent administration with warfarin can result in clinically significant increases in coagulation parameters: Closely monitor INR and prothrombin time. (5.9)
  • …
5.1 Serious Adverse Reactions or Death from Dihydropyrimidine Dehydrogenase (DPD) Deficiency

5.1 Serious Adverse Reactions or Death from Dihydropyrimidine Dehydrogenase (DPD) Deficiency Patients with certain homozygous or compound heterozygous variants in the DPYD gene known to result in complete or near complete absence of DPD activity (complete DPD deficiency) are at increased risk for acute early-onset toxicity and serious, including fatal adverse reactions due to FAVLYXA (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity (partial DPD deficiency) may also have increased risk of serious or fatal adverse reactions.

Prior to initiating FAVLYXA, test patients for genetic variants of the DPYD gene unless immediate treatment is necessary [see Clinical Pharmacology (12.5)]. Serious adverse reactions may still occur even if no DPYD variants are identified. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency.

Withhold or permanently discontinue FAVLYXA based on clinical assessment of the onset, duration, and severity of adverse events in patients with evidence of acute early-onset or unusually severe reactions. No fluorouracil dose has been proven safe for patients with complete DPD deficiency. For patients with partial DPD deficiency, individualize the dosage and modify based on tolerability and intent of treatment.

An FDA-authorized test for the detection of genetic variants of the DPYD gene to identify patients at risk of serious adverse reactions with FAVLYXA treatment is not currently available. Currently available tests used to identify DPYD variants may vary in accuracy and design (e.g., which DPYD variant(s) they identify).

5.2 Cardiotoxicity

5.2 Cardiotoxicity FAVLYXA can cause cardiotoxicity, including angina, myocardial infarction/ischemia, arrhythmia, and heart failure, based on postmarketing reports. Reported risk factors for cardiotoxicity are administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease. Withhold FAVLYXA for cardiotoxicity.

The risks of resumption of FAVLYXA in patients with cardiotoxicity that has resolved have not been established [see Dosage and Administration (2.3)].

5.3 Hyperammonemic Encephalopathy

5.3 Hyperammonemic Encephalopathy FAVLYXA can cause hyperammonemic encephalopathy in the absence of liver disease or other identifiable cause, based on postmarketing reports. Signs or symptoms of hyperammonemic encephalopathy began within 72 hours after initiation of FAVLYXA infusion; these included altered mental status, confusion, disorientation, coma, or ataxia, in the presence of concomitant elevated serum ammonia level.

Withhold FAVLYXA for hyperammonemic encephalopathy and initiate ammonia-lowering therapy. The risks of resumption of FAVLYXA in patients with hyperammonemic encephalopathy that has resolved have not been established [see Dosage and Administration (2.3)].

5.4 Neurologic Toxicity

5.4 Neurologic Toxicity FAVLYXA can cause neurologic toxicity, including acute cerebellar syndrome and other neurologic events, based on postmarketing reports. Neurologic symptoms included confusion, disorientation, ataxia, or visual disturbances. Withhold FAVLYXA for neurologic toxicity. There are insufficient data on the risks of resumption of FAVLYXA in patients with neurologic toxicity that has resolved [see Dosage and Administration (2.3)].

5.5 Diarrhea

5.5 Diarrhea FAVLYXA can cause severe diarrhea. Withhold FAVLYXA for Grade 3 or 4 diarrhea until resolved or decreased in intensity to Grade 1, then resume FAVLYXA at a reduced dose. Administer fluids, electrolyte replacement, or antidiarrheal treatments as necessary [see Dosage and Administration (2.3)].

5.6 Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome)

5.6 Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) FAVLYXA can cause palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS). Symptoms of HFS include a tingling sensation, pain, swelling, and erythema with tenderness, and desquamation. HFS occurs more commonly when fluorouracil is administered as a continuous infusion than when fluorouracil is administered as a bolus injection, and has been reported to occur more frequently in patients with previous exposure to chemotherapy.

HFS is generally observed after 8 to 9 weeks of fluorouracil administration but may occur earlier. Institute supportive measures for symptomatic relief of HFS. Withhold FAVLYXA administration for Grade 2 or 3 HFS; resume FAVLYXA at a reduced dose when HFS is completely resolved or decreased in severity to Grade 1 [see Dosage and Administration (2.3)].

5.7 Myelosuppression

5.7 Myelosuppression FAVLYXA can cause severe and fatal myelosuppression which may include neutropenia, thrombocytopenia, and anemia. The nadir in neutrophil counts commonly occurs between 9 and 14 days after fluorouracil administration. Obtain complete blood counts prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as needed.

Withhold FAVLYXA until Grade 4 myelosuppression resolves; resume FAVLYXA at a reduced dose when myelosuppression has resolved or improved to Grade 1 in severity [see Dosage and Administration (2.3)].

5.8 Mucositis

5.8 Mucositis FAVLYXA can cause mucositis, stomatitis or esophagopharyngitis, which may lead to mucosal sloughing or ulceration. The incidence is reported to be higher with administration of fluorouracil by intravenous bolus compared with administration by continuous infusion. Withhold FAVLYXA administration for Grade 3 or 4 mucositis; resume FAVLYXA at a reduced dose once mucositis has resolved or decreased in severity to Grade 1 [see Dosage and Administration (2.3)].

5.9 Increased Risk of Bleeding with Concomitant Use of Warfarin

5.9 Increased Risk of Bleeding with Concomitant Use of Warfarin Altered coagulation parameters and/or bleeding, including death, have been reported during concomitant use of warfarin and fluorouracil. Monitor INR more frequently and adjust the dose of warfarin in patients receiving concomitant warfarin [see Drug Interactions (7)].

5.10 Embryofetal Toxicity

5.10 Embryofetal Toxicity Based on its mechanism of action and animal reproduction studies, FAVLYXA can cause fetal harm when administered during pregnancy [see Use in Specific Populations (8.1), and Clinical Pharmacology (12.1)]. Advise females of reproductive potential to use effective contraception during treatment with FAVLYXA and for 6 months after the last dose.

Advise males with female partners of reproductive potential to use effective contraception during treatment with FAVLYXA and for 3 months after the last dose [see Use in Specific Populations (8.3)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS 7.1 Effect of FAVLYXA on Other Drugs Vitamin K Antagonists Monitor INR and PT more frequently in patients receiving FAVLYXA and warfarin. Elevated INR and PT have been reported in patients taking fluorouracil concomitantly with warfarin.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Serious adverse reactions or death from Dihydropyrimidine Dehydrogenase (DPD) deficiency [see Warnings and Precautions (5.1)] Cardiotoxicity [see Warnings and Precautions (5.2)] Hyperammonemic encephalopathy [see Warnings and Precautions (5.3)] Neurologic toxicity [see Warnings and Precautions (5.4)] Diarrhea [see Warnings and Precautions (5.5)] Palmar-plantar erythrodysesthesia (hand-foot syndrome) [see Warnings and Precautions (5.6)] Myelosuppression [see Warnings and Precautions (5.7)] Mucositis [see Warnings and Precautions (5.8)] Increased risk of bleeding with concomitant use of warfarin [see Warnings and Precautions (5.9)] To report SUSPECTED ADVERSE REACTIONS, contact Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of fluorouracil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hematologic: pancytopenia [see Warnings and Precautions (5.7)] Gastrointestinal: gastrointestinal ulceration, nausea, vomiting Allergic Reactions: anaphylaxis and generalized allergic reactions Neurologic: nystagmus, headache Dermatologic: dry skin; fissuring; photosensitivity, as manifested by erythema or increased pigmentation of the skin; vein pigmentation Ophthalmic: lacrimal duct stenosis, visual changes, lacrimation, photophobia Psychiatric: euphoria Miscellaneous: thrombophlebitis, epistaxis, nail changes (including loss of nails)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on mechanism of action and animal reproduction studies, FAVLYXA can cause fetal harm when administered during pregnancy [see Clinical Pharmacology (12.1)]. Available data from observational studies with intravenous administration of fluorouracil during pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

Administration of fluorouracil to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. Malformations included cleft palate and skeletal defects. In monkeys, maternal doses of fluorouracil higher than an approximate human dose of 12 mg/kg resulted in abortion (see Data).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Data Animal Data Malformations including cleft palate, skeletal defects and deformed appendages (paws and tails) were observed when fluorouracil was administered by intraperitoneal injection to mice at doses at or above 10 mg/kg (approximately 0.06 times a human dose of 12 mg/kg on a mg/m 2 basis) for 4 days during the period of organogenesis.

Similar results were observed in hamsters administered fluorouracil intramuscularly at doses lower than those administered in commonly used clinical treatment regimens. In rats, administration of fluorouracil by intraperitoneal injection at doses greater than 15 mg/kg (approximately 0.2 times a human dose of 12 mg/kg on a mg/m 2 basis) for a single day during organogenesis resulted in delays in growth and malformations including micro-anophthalmos.

In monkeys, administration of fluorouracil during organogenesis at doses approximately equal to a human dose of 12 mg/kg on a mg/m 2 basis resulted in abortion; at a 50% lower dose, resorptions and decreased fetal body weights were reported.

Mechanism of action

12.1 Mechanism of Action Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′-triphosphate (FdUTP).

These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and incorporation of FdUTP into DNA.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Fluorouracil exposure-response relationships and the time course of the pharmacodynamic response are unknown.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Following bolus intravenous injection, 5 to 20% of the parent drug is excreted unchanged in the urine in six hours.

The metabolites of fluorouracil (e.g., urea and α-fluoro-ßalanine) are excreted in the urine over 3 to 4 hours.

Following bolus intravenous injection of fluorouracil, as a single agent, the elimination half-life increased with dose from 8 to 20 minutes.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Distribution Following bolus intravenous injection, fluorouracil distributes throughout the body including the intestinal mucosa, bone marrow, liver, cerebrospinal fluid and brain tissue. Elimination Following bolus intravenous injection, 5 to 20% of the parent drug is excreted unchanged in the urine in six hours.

The remaining percentage of the administered dose is metabolized, primarily in the liver. The metabolites of fluorouracil (e.g., urea and α-fluoro-ßalanine) are excreted in the urine over 3 to 4 hours. Following bolus intravenous injection of fluorouracil, as a single agent, the elimination half-life increased with dose from 8 to 20 minutes.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Fluorouracil 50 mg/mL, 10 mL Vial₱64.00–₱75.00Reference ₱66.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Fluorouracil
PNF listingInj.: 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. FAVLYXA · Avyxa Pharma, LLC [US FDA-approved label, version 8, October 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1daf714b-704c-4bcc-b6e0-6f0eb2bfe66b
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .